How to Request RMN Data and Samples?
To advance infertility research, the Reproductive Medicine Network (RMN) has decided to share resources (samples and data) with investigators at large. The RMN resources will be provided based on the availability of the resources, the priority of the RMN mission, and the scientific significance assessed by an external scientific review (i.e. NIH study section), and the evidence of secured funding by the requesting investigators. Please refer to the Reviewer Form for our review criteria.
The requesting investigators must cover all costs associated with their requests including, but not limited to, shipping specimen and preparing data files. These costs can be difficult to estimated, and we will make every effort to provide information to the investigators.
Submitting a Request
A flow chart of the resource requesting and reviewing process is available. Investigators need to submit the following documents to firstname.lastname@example.org:
- Letter of interest to make an initial inquiry
- Research proposal when invited by the RMN (Please refer to the Concept Proposal Submission Form)
- Signed User Agreement for Accessing RMN Resources after receiving an approval letter from the RMN and before the data and/or samples are released
Reviews of requests take place on a quarterly basis. A decision letter will be sent to the requesting investigators immediately after the decision is made.
These policies apply to all investigators whether or not they are RMN investigators.
Existing Data and Samples
Investigators are encouraged to review the description of the currently available data and samples before proceeding with their requests.
The RMN sites enrolled 900 couples with unexplained infertility in a multicenter, randomized trial in which women (ages 18-40) were randomly assigned to ovarian stimulation (up to four cycles) to examine whether treatment of infertile women with an aromatase inhibitor (AI) results in a lower rate of multiple gestations than the current standard ovulation induction medications of clomiphene citrate (CC) or gonadotropin. The following information includes: the primary paper, additional publications, protocol and available data and samples.
In this double-blind, multicenter trial, the RMN enrolled 750 couples in which women with PCOS (ages 18-40) were randomly assigned to receive letrozole or clomiphene to determine which of these medications improved live birth rate. The following information includes: the primary paper, additional publications, protocol and available data and samples.
This multicenter randomized controlled trial enrolled 626 couples in which infertile women with PCOS (ages 18-39) received clomiphene citrate plus placebo, extended-release metformin plus placebo, or a combination of metformin and clomiphene to evaluate the superior ovulation induction treatment for achieving live birth. The following information includes: the primary paper, protocol and available data and samples.
This multicenter randomized controlled trial randomly assigned 932 couples (women 40 years old or younger; men 55 years old or younger) with unexplained infertility to receive intracervical insemination, intrauterine insemination, superovulation and intracervical insemination, or superovulation and intrauterine insemination to evaluate the efficacy of ovulation induction on achieving pregnancy. The following information includes: the primary paper, protocol and available data and samples.